361 related articles for article (PubMed ID: 21148517)
1. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
[TBL] [Abstract][Full Text] [Related]
2. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
Stryjewski ME; Lentnek A; O'Riordan W; Pullman J; Tambyah PA; Miró JM; Fowler VG; Barriere SL; Kitt MM; Corey GR
BMC Infect Dis; 2014 May; 14():289. PubMed ID: 24884578
[TBL] [Abstract][Full Text] [Related]
3. Telavancin: a review of its use in patients with nosocomial pneumonia.
Scott LJ
Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
[TBL] [Abstract][Full Text] [Related]
4. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
5. Telavancin.
Lyseng-Williamson KA; Blick SK
Drugs; 2009; 69(18):2607-20. PubMed ID: 19943710
[TBL] [Abstract][Full Text] [Related]
6. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.
Torres A; Rubinstein E; Corey GR; Stryjewski ME; Barriere SL
J Antimicrob Chemother; 2014 Apr; 69(4):1119-26. PubMed ID: 24398339
[TBL] [Abstract][Full Text] [Related]
8. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
9. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
10. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
Polyzos KA; Mavros MN; Vardakas KZ; Makris MC; Rafailidis PI; Falagas ME
PLoS One; 2012; 7(8):e41870. PubMed ID: 22916113
[TBL] [Abstract][Full Text] [Related]
12. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
Stryjewski ME; Barriere SL; O'Riordan W; Dunbar LM; Hopkins A; Genter FC; Corey GR
J Antimicrob Chemother; 2012 Jun; 67(6):1496-502. PubMed ID: 22416054
[TBL] [Abstract][Full Text] [Related]
14. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
15. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
[TBL] [Abstract][Full Text] [Related]
16. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
[TBL] [Abstract][Full Text] [Related]
17. The role of telavancin in the treatment of MRSA infections in hospital.
Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
[TBL] [Abstract][Full Text] [Related]
18. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
[TBL] [Abstract][Full Text] [Related]
19. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
Liapikou A; Dimakou K; Toumbis M
Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
[TBL] [Abstract][Full Text] [Related]
20. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials.
Niederman MS; Lee PC; Barriere SL; Barnes CN; Castaneda-Ruiz B
Infect Dis Ther; 2019 Sep; 8(3):445-452. PubMed ID: 31372837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
